注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   其他   >   EWSR1 Antibody (monoclonal) (M01)   

EWSR1 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant EWSR1.

     
  • 1 - EWSR1 Antibody (monoclonal) (M01) AT1961a
    Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (36.3 KDa) .
  • 1 - EWSR1 Antibody (monoclonal) (M01) AT1961a
    Western Blot analysis of EWSR1 expression in transfected 293T cell line by EWSR1 monoclonal antibody (M01), clone 5C10.

    Lane 1: EWSR1 transfected lysate(68.5 KDa).
    Lane 2: Non-transfected lysate.
  • 2 - EWSR1 Antibody (monoclonal) (M01) AT1961a
    Immunoperoxidase of monoclonal antibody to EWSR1 on formalin-fixed paraffin-embedded human urinary bladder. [antibody concentration 3 ug/ml]
  • 10 - EWSR1 Antibody (monoclonal) (M01) AT1961a
    Detection limit for recombinant GST tagged EWSR1 is approximately 0.03ng/ml as a capture antibody.
  • 产品详情
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB, IHC, E
Primary Accession Q01844
Other Accession NM_005243
Reactivity Human
Host mouse
Clonality monoclonal
Isotype IgG2a Kappa
Clone Names 5C10
Calculated MW 68478 Da
Additional Information
Gene ID 2130
Other Names RNA-binding protein EWS, EWS oncogene, Ewing sarcoma breakpoint region 1 protein, EWSR1, EWS
Target/Specificity EWSR1 (NP_005234, 358 a.a. ~ 453 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution WB~~1:500~1000
IHC~~1:100~500
E~~N/A
Format Clear, colorless solution in phosphate buffered saline, pH 7.2 .
StorageStore at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
PrecautionsEWSR1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

BACKGROUND

This gene encodes a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport. The protein includes an N-terminal transcriptional activation domain and a C-terminal RNA-binding domain. Chromosomal translocations between this gene and various genes encoding transcription factors result in the production of chimeric proteins that are involved in tumorigenesis. These chimeric proteins usually consist of the N-terminal transcriptional activation domain of this protein fused to the C-terminal DNA-binding domain of the transcription factor protein. Mutations in this gene, specifically a t(11;22)(q24;q12) translocation, are known to cause Ewing sarcoma as well as neuroectodermal and various other tumors. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 1 and 14.

REFERENCES

Detection of SYT and EWS gene rearrangements by dual-color break-apart CISH in liquid-based cytology samples of synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor. Kumagai A, et al. Am J Clin Pathol, 2010 Aug. PMID 20660338.Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Aryee DN, et al. Cancer Res, 2010 May 15. PMID 20442286.EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Riggi N, et al. Genes Dev, 2010 May. PMID 20382729.Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. Le Deley MC, et al. J Clin Oncol, 2010 Apr 20. PMID 20308673.Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. van Doorninck JA, et al. J Clin Oncol, 2010 Apr 20. PMID 20308669.

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价